Odronextamab yields 48.3% response in DLBCL
Odronextamab yields 48.3% response in DLBCL after CAR-T failure, per ELM-1 study, offering hope for relapsed patients
Related Articles
JACC Journals at China Valve 2025 | JACC: Case Reports
Discover cutting-edge advancements in valvular heart disease at the China Valve (Hangzhou) conference, chaired by Professor Jian’an Wang, with 2,000+ global attendees.
Dr. Oz Declares All-Out WAR on America’s Corrupt Healthcare System
As the new head of CMS, he just dropped the most aggressive plan we’ve ever seen to fix Medicare and Medicaid. You won’t believe what…
American College of Radiology to Expand Lung Cancer Screening Registry
The American College of Radiology (ACR) has announced that its Lung Cancer Screening Registry (LCSR) is expanding and will evolve into the Early Lung Cancer…
SOHO Insider – IsaPd Effective in Real-World Myeloma Study
IsaPd shows 74.1% response in real-world relapsed myeloma study, outperforming ICARIA-MM, per Haematologica.
Can Doing a Low Carb (Vegan Keto) Diet 1-2 Days a Week Improve Your Metabolism?: Joel Kahn, MD: Integrative Cardiologist
The good news? This new research suggests you may not have to slash your calories so drastically on fasting days – simply cutting out carbs…
Hematologic Oncology News | Blood Cancers Today
Blood Cancers Today provides hematologists and oncologists with news, education, and information relevant to their patients and practices, featuring exclusive expert interviews.
Significance of Coronary Artery Calcifications and Ischemic Electrocardiographic Changes Among Patients Undergoing Myocardial Perfusion Imaging:
AbstractBackgroundEstimation of coronary artery calcification (CAC) can provide important prognostic information in patients with suspected coronary artery disease.ObjectivesThe authors aimed to in…
CARE Award | Cancer Nursing Today
Nurses: Vote for your oncology nursing peers and colleagues who demonstrate resilience, role modeling, and high-level patient care for the CARE Award.
Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVER
AbstractBackgroundPatients with severe heart failure (HF) experience debilitating clinical symptoms and worse cardiovascular (CV) outcomes with an excess mortality risk.ObjectivesThe authors aimed …
Heart Failure Beat: HF Stats 2024: Addressing the Growing Heart Failure Crisis
Tune into the HF Beat as Dr. Biykem Bozkurt joins us to discuss the concerning rise in heart failure mortality rates in younger patients as…
